Riskpilot← Back to searchSign inGet full accessRavlic-Urologi AB
ABActiveOrg 5592698160Tallmovägen 2 BGeneral medical practice activities · NACE 8621Est. 20200 employees
Revenue 2024
SEK 2,7M
+10% vs 2023
EBITDA margin
60.7%
+29% vs 2023
Equity ratio
74.6%
Financial strength
Net profit 2024
SEK 1,1M
+10% vs 2023
| Revenue | SEK 2,7M | +10% |
| EBITDA | SEK 1,6M | +29% |
| Net profit | SEK 1,1M | +10% |
| Total assets | SEK 4,8M | +28% |
| Equity | SEK 3,6M | +28% |
| Employees | 0 | — |
Legal name
Ravlic-Urologi AB
Org number
5592698160
Legal form
Aktiebolag
NACE code
8621 · General medical practice activities
Founded
3 september 2020
Share capital
SEK 25 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Som specialist och överläkare inom urologi, främja god vård.
Address
Tallmovägen 2 B
Email
ravlicurologiab@gmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Revenue | 2 547 | 3 130 | 2 435 | 2 685 |
| Staff expenses | — | −798 | −841 | −809 |
| EBITDA | 1 157 | 2 056 | 1 261 | 1 631 |
| Depreciation & amort. | −0 | — | — | — |
| EBIT | 1 157 | 2 056 | 1 261 | 1 631 |
| Net financials | −15 | −0 | −5 | −20 |
| Profit before tax | 1 143 | 2 055 | 1 257 | 1 392 |
| Tax | −250 | −425 | −260 | −291 |
| Net profit | 893 | 1 631 | 996 | 1 101 |
| Item | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Total assets | 1 370 | 3 037 | 3 757 | 4 814 |
| Equity | 918 | 2 049 | 2 797 | 3 593 |
| Long-term debt | 0 | — | — | — |
| Short-term debt | 452 | 989 | 960 | 1 001 |
| Total debt | 452 | 989 | 960 | 1 001 |
EBITDA margin
60.7%
This company
15.8%
Market median
+284% vs market
20212024
Equity ratio
74.6%
This company
38.2%
Market median
+95% vs market
20212024
Return on equity
30.6%
This company
18.4%
Market median
+66% vs market
20212024
Net profit margin
41.0%
This company
8.1%
Market median
+406% vs market
20212024
Asset turnover
0.56×
This company
1.12×
Market median
-50% vs market
20212024
Debt / equity
0.34×
This company
0.62×
Market median
+45% vs market
20212024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-09-01 – 2021-12-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Deputy Board Member | 2024 | |
| Board of Directors | 2020 | |
| Former (2) | ||
| Deputy Board Member | 2020 – 2022 | |
| Deputy Board Member | 2022 – 2024 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Ravlic-Urologi AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Martina Ravlic | Deputy Board Member | 0 companies |
| Martina Ravlic | Deputy Board Member | 0 companies |
| Anna Lovisa Strålöga | Deputy Board Member | 0 companies |
| Mario Ravlic | Board of Directors | 0 companies |